Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALZT-OP1a in Post-Ischemic Stroke Cognitive Impairment
NCT03202147Phase 2Withdrawn
- Sponsor
- AZTherapies
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in post-stroke cognitive impairment (PSCI) (2 arms), sponsored by AZTherapies. Primary endpoint: Montreal Cognitive Assessment at 12 weeks. Planned start Dec 2023; status: withdrawn.
02
Conditions
post-stroke cognitive impairment (PSCI)
Beyond the preview
Go deeper on NCT03202147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202147.